One study has shown that, a targeted surveillance approach for ACC in TP53 mutation carriers before age 15, decreases at-diagnosis tumor size with a trend towards lower stage and increased surgical cure in the surveillance group [22]. The gene discussed is TP53; the disease is neoplasm.